Anfoleish (CL)
Develop a topical anti-parasitic treatment containing amphotericin B for the treatment of CL
last phase of drug development




updated 31 Aug 2016
The rationale for development of a topical formulation of amphotericin B was to provide a treatment to be applied locally at the CL lesion, showing high anti-parasitic effect, but without the systemic toxicity associated with amphotericin B. A Phase Ib/II open-label, randomized, non-comparative, two-arm exploratory study is being conducted in Colombia. Initially planned to include only patients with CL caused by L. braziliensis, recruitment was widened to include patients with CL caused by L. panamensis. Enrolment of all 80 patients was completed in November 2015, and preliminary data on cure will be available in 2016.
If Anfoleish is shown to be efficacious against L. braziliensis and L. panamesis, a multi-country Phase III study will be planned in Latin America.
- Brazil - Ministry of Health Brazil
- Colombia - Ruta-N / City of Medellin
- Europe - European Union – Framework Programme 7
- Spain - Spanish Agency for International Development Cooperation (AECID)
- Switzerland - Swiss Agency for Development and Cooperation (SDC)
- The Netherlands - Dutch Ministry of Foreign Affairs (DGIS)
- UK - UK International Development
- Bem-Te-Vi Diversidade
- Médecins Sans Frontières International
- Other private foundations and individuals
- The Rockefeller Foundation (through the “Next Century Innovators Award”)
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.